Max-Hervé George Details SWI's Investment Case for Underground AI and Data Infrastructure
Opinions expressed by Entrepreneur contributors are their own.
You're reading Entrepreneur Asia Pacific, an international franchise of Entrepreneur Media.
SWI Group, a recently merged entity formed from Stoneweg and Icona Capital with over €10 billion in assets under management, has broadened its investment remit to include digital infrastructure across Europe. Known for its pan-European real assets platform and alternatives strategy, the group is now building out foundational technologies that support intelligent systems.
"We are at the start of a secular transformation in how data is processed, stored, and monetized," said Max-Hervé George. "Our aim is to invest not just in trends, but in foundations."
SWI Group, under the leadership of Max-Hervé George, has begun acquiring and developing AI-ready data centers, edge compute nodes, and sovereign compute regions in locations selected for access to renewable energy, regulatory stability, and potential for future expansion. This infrastructure push represents a strategic shift that aligns SWI's long-term capital cycle with Europe's growing demand for compliant and resilient compute capacity.
In parallel, SWI is retrofitting brownfield sites to meet state‑of‑the‑art technical and sustainability benchmarks. Modular designs and efficient cooling systems are being deployed to ensure adherence to EU ESG regulations and prepare for forthcoming AI‑centric frameworks.
Leveraging its combined structure—Stoneweg Real Assets and Icona Alternatives—SWI benefits from deep expertise in structured finance, thematic investing, and operational delivery. That cross‑functional advantage strengthens the underwriting of complex digital infrastructure.
The current pipeline spans enterprise, government, and cloud‑oriented facilities offering stable, utility‑style revenue and diversified use cases. With Europe sharpening its focus on secure and ethically aligned AI deployment, SWI's infrastructure play reflects both commercial foresight and robust institutional support.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best hot stocks to buy according to Wall Street analysts. On July 3, Bloomberg News reported that AstraZeneca (NASDAQ:AZN) is in discussions with Summit Therapeutics for a licensing agreement concerning an experimental lung cancer drug, with a potential value of up to $15 billion. The proposed deal for the drug, which is known as ivonescimab, could involve an upfront payment of several billion dollars to Summit, in addition to future milestone payments. However, the talks are ongoing and could still fall apart. Summit might even choose to partner with a different company. Neither Summit nor AstraZeneca has officially commented on the report. A laboratory employee in a sterile environment inspecting a microscope focused on a Clostridioides difficile infection sample. Summit Therapeutics secured the rights to ivonescimab through a separate deal worth up to $5 billion with China-based Akeso in December 2022. Under that agreement, Summit gained exclusive rights to develop and commercialize ivonescimab in the US, Canada, Europe, and Japan, while Akeso (OTC:AKESF) retained rights for other regions, including China. The deal included an upfront payment of $500 million to Akeso and potential regulatory and commercial milestones of up to $4.5 billion. Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company that discovers, develops, and commercializes patient, physician, caregiver, and societal-friendly medicinal therapies. AstraZeneca (NASDAQ:AZN) is a biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines. While we acknowledge the potential of SMMT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
37 minutes ago
- Associated Press
DentScribe Launches GPS - AI-Powered "Guided Production System" Transforming Dental Practice Operations and Revenue Optimization
SAN JOSE, Calif., July 6, 2025 /PRNewswire/ -- today announced the launch of DentScribe GPS (Guided Production System), a groundbreaking addition to its AI-powered dental software suite, building upon the successful DentScribe CoPilot. DentScribe GPS provides dental practices with a comprehensive, practice-wide view of patient care, production opportunities, and actionable insights drawn directly from the dentist's AI-generated SOAP notes. Unlike traditional dashboards based on static diagnostic imaging (e.g., x-rays), DentScribe GPS leverages the dentist's own professional assessments captured in SOAP notes, reflecting the 'ground truth' of clinical needs and treatment plans. This real-time AI analysis ensures precise identification of high-value production opportunities, urgent patient care interventions, and daily operational priorities. DentScribe GPS delivers its insights through a user-friendly, tablet-first interface specifically optimized for morning huddles and daily planning sessions. Dental teams gain immediate visibility into critical alerts, planned production, patient follow-ups, and comprehensive practice performance metrics. DentScribe GPS visually categorizes opportunities by urgency, provider, discipline, and financial value, empowering teams to prioritize effectively. Dr. Vinni K. Singh, DDS, founder and CEO of remarked, 'DentScribe GPS changes everything about our morning huddles. We now start each day knowing exactly where to focus our efforts to maximize both patient care and practice profitability. By harnessing AI-driven insights directly from our SOAP notes, we are identifying care opportunities and revenue streams that diagnostic tools alone simply cannot see.' Early adopters report significant practice improvements, including: DentScribe GPS includes a unique Daily Brief (DentScribe GPS Intelligence), which provides a concise summary of critical daily priorities, revenue optimization strategies, and team productivity goals. Dental teams can quickly review key insights and make informed decisions at the start of each day. DentScribe GPS is now available nationwide, building upon the success of DentScribe CoPilot and further establishing DentScribe as the market leader in AI-driven dental practice management. To see DentScribe GPS in action and experience immediate, measurable results in your dental practice, schedule a demo today at Media Contact: [email protected] View original content to download multimedia: SOURCE DentScribe
Yahoo
an hour ago
- Yahoo
Should You Buy This AI Stock That Soared 800% Last Year and Has a $140 Billion Total Addressable Market?
This company has reported accelerating revenue growth in recent quarters, and in the latest period, revenue soared more than 150%. After great gains last year, the stock slipped 45% in the first half of this year. 10 stocks we like better than SoundHound AI › Last year was a big one for artificial intelligence (AI) stocks, with companies in the sector leading all three major benchmarks to gains. Though the momentum halted temporarily earlier this year, as investors worried about the impact of import tariffs on the economy, this positive energy has returned. Investors are optimistic that trade talks will result in lower-than-expected tariffs, limiting the negative effects on companies, and that has buoyed interest in growth players, including AI stocks. Some AI stocks, though, have yet to feel the rebound. Considering the long-term AI growth story hasn't changed, these players may offer you bargain buying opportunities today. Let's consider one in particular. This AI stock surged more than 800% in 2024 but dropped 45% in the first half of this year. Meanwhile, it's a specialist in its field, one with a total addressable market of more than $140 billion. Is this player a buy right now? The AI stock I'm talking about is SoundHound AI (NASDAQ: SOUN), a company with expertise in voice AI, reinforced by more than 190 granted patents. Though other companies, even big players such as Amazon or Microsoft, are involved in the field, SoundHound stands out thanks to its speech-to-meaning technology. The company translates speech directly to meaning, bypassing the common step of translating speech to text first, therefore gaining in speed and quality. Customers clearly like SoundHound's offerings, as revenue has taken off, and the company has signed deals across industries. This is a key point because, in its earlier days, SoundHound primarily served the automobile industry. This strength in fields such as healthcare, retail, travel, and more, as well as the fact that no customer represents more than 10% of revenue, greatly reduces SoundHound's risk. That's because if one customer or industry cuts spending, others may compensate. SoundHound's revenue in the recent quarter advanced 151% to about $29 million, which is great. But what's even better is that the company still has plenty of room for growth, considering its current revenue level and the total addressable market of $140 billion, which spans 14 different industries. And the company has three ways to generate revenue: through royalties on its products, subscriptions for services, and taking additional revenue from the use of its products and services. Of course, despite SoundHound's expertise in the field, the company still faces the risk of major rivals, such as those mentioned above, gaining market share due to their immense resources. That's what makes SoundHound a stock that carries some risk right now, and even though the stock has slipped this year, the decline looks small compared to the gain posted last year. These factors could limit SoundHound's growth in the near term. Still, the company has seen growth accelerate in recent quarters, from 89% in the third quarter of last year to 101% in the fourth quarter and even higher in the most recent period. Further, as mentioned above, SoundHound may still be in its early stages of growth. So, what does this mean for you as an investor? Should you buy SoundHound now on the dip? The answer depends on your investment strategy. If you're a cautious investor, you're probably better off buying a larger, well-established player, such as Amazon or Microsoft, that may benefit from voice AI but also from broader, profitable businesses. Over time, they've proven their earnings and stock performance strengths. If you're an aggressive investor, though, SoundHound looks like a fantastic AI buy right now. The stock has slipped from its high, offering you a lower entry point. Revenue has clearly accelerated in recent quarters, and the company has successfully broadened its customer base across industries. On top of that, I like that SoundHound is financially healthy, with no debt and $246 million in cash. All this makes it a great AI stock to get in on right now and hang on to as its growth story develops. Before you buy stock in SoundHound AI, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and SoundHound AI wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $699,558!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $976,677!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Adria Cimino has positions in Amazon. The Motley Fool has positions in and recommends Amazon and Microsoft. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Should You Buy This AI Stock That Soared 800% Last Year and Has a $140 Billion Total Addressable Market? was originally published by The Motley Fool
